Scientific Presentations
2023
Tissue Assessment of Theraprutic Responses to Neoadjuvant SCRT with and without Anit-CD40 Immunotherapy Sotigalimab (Sotiga) in Rectal Cancer
ASCO-GI Poster 2023 | January 2023
Use of High-dimensional and Spatial Immune Profiling to Explore Sotigalimab (CD40 Agonist) Activation of Antigen Presenting Cells and T Cells in the Tumor Microenvironment in Patients with Esophageal/Gastroesophageal Junction Cancer
ASCO-GI Poster 2023 | January 2023
2022
Intratumoral Sotigalimab with Pembrolizumab Activates Antigen presenting cells and Induces Local and Distant Anti tumor Responses in First line Metastatic Melanoma: Results of a Phase I/II Study
SITC Presentation 2022 | November 2022
A Multicenter Phase 2 Study of Sotigalimab (CD40 Agonist) in Combination With Neoadjuvant Chemoradiation for Resectable Esophageal and Gastroesophageal Junction (GEJ) Cancers
ESMO Poster 2022 | September 2022
Distinct Biosignatures Associate with Survival After Chemoimmunotherapy in a Randomized, Three-arm Phase II Study in Patients with Metastatic Pancreatic Cancer
ASCO Presentation 2022 | June 2022
Intratumoral CD40 Agonist Sotigalimab (APX005M) with Pembrolizumab Induces Broad Innate and Adaptive Immune Activation in Local and Distant Tumors in Metastatic Melanoma
AACR Presentation 2022 | April 2022
Elucidating Factors of Therapeutic Response to Immunotherapy Combined with Neoadjuvant Radiation Therapy for Rectal Cancer
Keystone Poster 2022 | March 2022
2021
Multi-Omic Multi-Parameter Circulating Biomarker Analysis in Chemoimmunotherapy Combinations Identifies Unique Immune Activation Signatures in the Pancreatic Cancer Setting
SITC Poster 2021 | November 2021
Phase II of CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
SITC Poster 2021 | November 2021
Innate: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer to Elucidate Local and Systemic Therapeutic Response
SITC Poster 2021 | November 2021
Gemcitabine and nab-Paclitaxel ± Nivolumab ± CD40 Agonistic Monoclonal Antibody Sotigalimab (APX005M) in Participants with Untreated Metastatic Pancreatic Adenocarcinoma: Phase 2 Final Results
ASCO Poster 2021 | June 2021
2020
First in Pediatrics Phase 1 Study Of CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/Refractory Brain Tumors
ISPNO Presentation | December 2020
A Phase II Trial with a Safety Lead-in to Evaluate the Addition of APX005M, a CD40 Agonistic Monoclonal Antibody, to Standard-of-Care Doxorubicin for the Treatment of Patients with Advanced Sarcoma
ASCO SITC Poster | February 2020
2019
Intratumoral CD40 Agonist (APX005M) in Combination with Pembrolizumab Induces Broad Innate and Adaptive Immune Activation in Local and Distant Tumors in CPI Treatment Naïve Metastatic Melanoma
CICON Poster | September 2019
Phase 1b/2 Study of CD40 Agonistic Antibody APX005M in Combination with Nivolumab (Nivo) in Subjects with Metastatic Melanoma (M) and Subjects with Non-Small Cell Lung Cancer (NSCLC)
AACR Poster | April 2019
A Phase 1b Study of CD40 Agonistic Monoclonal Antibody APX005M Together with Gemcitabine and nab-Paclitaxel with or without Nivolumab in Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Patients
AACR Presentation | March 2019
A Phase 1b Study of CD40 Agonistic Monoclonal Antibody APX005M Together with Gemcitabine and nab-Paclitaxel with or without Nivolumab in Untreated Metastatic Ductal Pancreatic Adenocarcinoma (PDAC) Patients
ASCO GI Abstract | January 2019
2018
Phase I/II Dose Escalation and Expansion Study of Image Guided Intratumoral APX005M in Combination with Systemic Pembrolizumab in Treatment Naive Metastatic Melanoma Patients
ASCO Poster | June 2018
2017
First in Human Study with the CD40 Agonistic Monoclonal Antibody APX005M in Subjects with Solid Tumors
SITC Presentation | November 2017
Phase 1 Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Subjects with Solid Tumors
SITC Poster | November 2017
A Pilot Study to Evaluate The Clinical and Immunological Effects of Incorporating a CD40-Agonistic Antibody into the Multimodality Treatment of Resectable Esophageal and GE Junction Cancersrcoma
SITC Poster | November 2017
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma
SITC Poster | November 2017
A Phase Ib/II Study of CD40 Agonistic Monoclonal Antibody (APX005M) Together with Gemcitabine and nab-Paclitaxel with or without Nivolumabin Untreated Metastatic Pancreatic Adenocarcinoma Patients
SITC Poster | November 2017